Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…Abstract Number: 1657 • ACR Convergence 2025
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are cornerstones of autoimmune‑disease therapy, yet many patients switch agents because of loss of effectiveness, adverse events, or insurance…Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…Abstract Number: 0202 • ACR Convergence 2025
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections due to both immune system dysfunction and the use of immunosuppressive…
- 1
- 2
- 3
- …
- 21
- Next Page »